Vitamin D and calcium supplementation in women undergoing pharmacological management for postmenopausal osteoporosis: a level I of evidence systematic review

Migliorini, Filippo; Maffulli, Nicola; Colarossi, Giorgia; Filippelli, Amelia; Memminger, Michael; Conti, Valeria

doi:10.1186/s40001-025-02412-x

Table 1 Study characteristics and patient data at baseline of the included studies

From: Vitamin D and calcium supplementation in women undergoing pharmacological management for postmenopausal osteoporosis: a level I of evidence systematic review

Author, year	Journal	Mean follow-up (months)	Mean calcium daily supplement (mg)	Mean vit D daily supplement (UI)	Treatment	Samples (n)	Mean age	Mean BMI (kg/m2)
Anastasilakis et al. [35]	Osteoporos Int	12	1000	800	Denosumab	32	63	28.80
Anastasilakis et al. [35]	Osteoporos Int	12	1000	800	Zoledronate	26	63	28.70
Atmaca et al. [36]	Adv Ther	12	600	400	Alendronate	16	66
Atmaca et al. [36]	Adv Ther	12	600	400	Risedronate	14	66
Bai et al. [37]	J Int Med Res	24	600	400	Zoledronate	242	57	23.44
Bai et al. [37]	J Int Med Res	24	600	400	Placebo	241	57	23.73
Body et al. [38]	J Clin Endocrinol Metab	14	1000	400–1200	Alendronate	73	65	24.40
Body et al. [38]	J Clin Endocrinol Metab	14	1000	400–1200	Teriparatide	73	66	23.90
Bone et al. [39]	J Clin Endocrinol Metab	24	813		Alendronate	86	71
			880		Alendronate	89	70
			831		Alendronate	93	71
			900		Placebo	91	71
Brumsen et al. [40]	J Bone Min Res	60	500	400	Pamidronate	26	66
Brumsen et al. [40]	J Bone Min Res	60	500	400	Placebo	27	64
Chesnut et al. [41]	J Bone Min Res	36	500	400	Ibandronate	977	69	26.20
					Ibandronate	977	69	26.20
					Placebo	975	69	26.20
Chung et al. [42]	Calcif Tissue Int	6	500	125	Ibandronate/risedronate	176	61	23.30
Chung et al. [42]	Calcif Tissue Int	6	500	125	Risedronate/ibandronate	176	62	23.40
Clemmesen et al. [43]	Osteoporos Int	36	1000		Risedronate	44	67	25.50
					Risedronate/placebo	44	68	24.40
					Placebo	44	70	25.10
Cummings et al. [44]	JAMA	48	634		Alendronate	2214	68	24.90
Cummings et al. [44]	JAMA	48	638		Placebo	2218	68	25.00
Cummings et al. [45]	New England J Med	36	1000	400–800	Denosumab	3902	72	26.00
Cummings et al. [45]	New England J Med	36	1000	400–800	Placebo	3906	72	26.00
Delmas et al. [46]	J Clin Endocrinol Metab	48	500	400–600	Raloxifene	2259	66	25.30
					Raloxifene	2277	66	25.20
					Placebo	2292	67	25.30
Ettinger et al. [47]	JAMA	36	500	400–600	Raloxifene	2259	67
					Raloxifene	2277
					Placebo	2292
Fogelman et al. [48]	J Clin Endocrinol Metab	24	1000		Risedronate	184	65	24.80
			1000		Risedronate	177	65	24.80
					Placebo	180	64	25.50
Gonnelli et al. [49]	Bone	12	841	400	Zoledronate	30	66	26.10
Gonnelli et al. [49]		12	870		Ibandronate	30	67	25.70
Greenspan et al. [50]	JAMA	24	807	163	Zoledronate	89	85	28.20
Greenspan et al. [50]	JAMA	24	763	168	Placebo	92	86	26.90
Grey et al. [51]	J Clin Endocrinol Metab	24	935		Zoledronate	25	62
Grey et al. [51]	J Clin Endocrinol Metab	24	916		Placebo	25	65
Grey et al. [52]	J Clin Endocrinol Metab	12	960		Zoledronate	43	64
			880		Zoledronate	43	66
			850		Zoledronate	43	66
			950		Placebo	43	65
Guanabens et al. [53]	Hepatology	24	1000		Ibandronate	14	65	26.60
Guanabens et al. [53]	Hepatology	24	1000		Alendronate	19	63	26.60
Harris et al. [54]	Am J Med	48	500		Phosphate–etidronate	63
					Placebo–etidronate	65
					Phosphate–placebo	62
					Placebo	63
Harris et al. [55]	JAMA	36	1000	500	Risedronate	817	69	26.60
					Risedronate	821	69	26.60
					Placebo	820	68	26.50
Iwamoto et al. [56]	J Orthop Sci	24	800	400	Etidronate	25	64	21.20
					Menatetrenone	23	65	20.60
					Control (calcium lactate)	24	66	20.90
Liberman et al. [57]	New England J Med	36	500		Alendronate	175	64	24.20
					Alendronate	175
					Alendronate	175
					Placebo	355	64	24.10
Lufkin et al. [58]	J Bone Min Res	12			Raloxifene	48	67	24.80
					Raloxifene	47	67	26.20
			750	400	Calcium/ Vit D	48	68	25.30
McClung et al. [59]	New England J Med	12	1000	800	Romosozumab	44	67
					Romosozumab	46	67
					Romosozumab	49	67
					Romosozumab	52	67
					Romosozumab	53	67
					Alendronate	47	67
					Teriparatide	46	67
					Placebo	47	67
McClung et al. [60]	J Bone Min Res	12	1000	800	Denosumab	127	67
McClung et al. [60]	J Bone Min Res	12	1000	800	Placebo	131	67
Meunier et al. [61]	New England J Med	36	1000	400–800	Strontium ranelate	719	69	26.20
Meunier et al. [61]	New England J Med	36	1000	400–800	Placebo	723	69	26.20
Meunier et al. [62]	Osteoporos Int	12	1000	400–800	Strontium ranelate	221	72
					Strontium ranelate	434	72
					Placebo	225	72
Miller et al. [63]	J Clin Endocrinol Metab	12	1000	800	Denosumab	321	69	24.30
Miller et al. [63]	J Clin Endocrinol Metab	12	1000	800	Zoledronate	322	70	24.30
Mortensen et al. [64]	J Clin Endocrinol Metab	36	937		Risedronate	37	52
			1057		Risedronate	38	51
			936		Placebo	36	51
Neer et al. [65]	New England J Med	24	1000	400–1200	Teriparatide	444	69
					Teriparatide	434	70
					Placebo	448	69
Paggiosi et al. [66]	Osteoporos Int	24	1200	800	Alendronate	57	68	25.90
					Ibandronate	58	67	26.40
					Risedronate	57	67	26.80
					Control	226	38	25.10
Peretz et al. [67]	Maturitas	24	500	400	Alendronate	18	68
Peretz et al. [67]	Maturitas	24	500	400	Pamidronate	21	70
Recknor et al. [68]	Obstet Gynecol	12	500	800	Denosumab	417	67	25.50
Recknor et al. [68]	Obstet Gynecol	12			Ibandronate	416	66	25.10
Reginster et al. [69]	Osteoporos Int	36	1000	500	Risedronate	410	71
					Risedronate	408	71
					Placebo	408	71
Sanad et al. [70]	Climacteric	12	1500	400	Raloxifene	35	63	26.50
					Alendronate	31	62	25.80
					Raloxifene/ alendronate	32	63	26.30
Tucci et al. [71]	Am J Med	36	500		Alendronate	98	67	23.90
					Alendronate	94	64	23.30
					Alendronate	94	64	23.70
					Placebo	192	64	23.80

Back to article page

ISSN: 2047-783X

Contact us

General enquiries: journalsubmissions@springernature.com

European Journal of Medical Research

Contact us